Talaris Therapeutics (TALS) and Tourmaline Bio Announce Merger Agreement

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. LEVI
2. APLD
3. STZ
4. SPY
5. RMR
6. DVN
7. CRGY
8. ZETA
9. ARGX
10. GOOGL

Go back to Talaris Therapeutics (TALS) and Tourmaline Bio Announce Merger Agreement

Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement

June 22, 2023 7:30 AM EDT

Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmalines anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD)

Combined company expected to have approximately $210 million of cash at the transaction close, including approximately $75 million from a concurrent private placement with leading life sciences investors

Strong balance sheet expected to support three clinical trials for TOUR006 including a Phase 2b trial in TED, a Phase 2 basket trial in additional TED cohorts,... More